Results 251 to 260 of about 158,299 (299)
Some of the next articles are maybe not open access.

EMA's response to articles

BMJ, 2011
Two recent BMJ articles have given the European Medicines Agency (EMA) useful feedback from the academic community on its provision of information on the scientific review of medicines.1 2 The agency is grateful for and open to suggestions on how this can be improved.
openaire   +2 more sources

PRIME time at the EMA

Nature Reviews Drug Discovery, 2017
The European Medicines Agency's PRIME scheme to accelerate the development of promising drugs that address unmet medical needs has enrolled 19 products in its first year, showing considerable overlap with FDA breakthrough therapy designees but also key differences.
openaire   +2 more sources

EMA-FAMS

Multiple sclerosis (MS) is a progressive autoimmune and neurodegenerative disease. One of the major symptoms of MS is fatigue which interferes individually with daily life activities and declines performance during tasks. Measuring associations between fatigue and activity performance (i.e., activity-related fatigability) in real-life situations ...
Suikkanen, Sara   +6 more
openaire   +1 more source

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA

Pharmaceutics, 2021
Maria Begoña Delgado-Charro   +1 more
exaly  

Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials

Cancers, 2021
Gennaro Daniele   +2 more
exaly  

EMAS

2003
A.J. Edwards, Tony Edwards
openaire   +1 more source

Home - About - Disclaimer - Privacy